ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
Authors:
- Lora StojanovicLSLora Stojanovic
- Rachel AbbottsRARachel Abbotts
- Kaushelendra TripathiKaushelendra Tripathi
- Collin M. CoonCCCollin M. Coon
- Saranya RajendranSRSaranya Rajendran
- Elnaz Abbasi FaridEFElnaz Abbasi Farid
- Galen HostetterGHGalen Hostetter
- Joseph W. GuarnieriJGJoseph W. Guarnieri
- Douglas C. WallaceDWDouglas C. Wallace
- Sheng LiuSLSheng Liu
- Jun WanJun Wan
- Gennaro CalendoGCGennaro Calendo
- 13 January 2025
- journal article
- other
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (7) , 1183-1198
Abstract
DNA methyltransferase (DNMT) and PARP inhibitors induce a stimulator of IFN gene–dependent pathogen mimicry response (PMR) in ovarian and other cancers. In this study, we showed that combining DNMT and PARP inhibitors upregulates expression of the nucleic acid sensor NFX1-type zinc finger–containing 1 (ZNFX1) protein. ZNFX1 mediated the induction of PMR in mitochondria, serving as a gateway for stimulator of IFN gene–dependent IFN/inflammasome signaling. Loss of ZNFX1 in ovarian cancer cells promoted proliferation and spheroid formation in vitro and tumor growth in vivo. In patient ovarian cancer databases, expression of ZNFX1 was elevated in advanced stage disease, and ZNFX1 expression alone significantly correlated with an increase in overall survival in a phase III trial for patients with therapy-resistant ovarian cancer receiving bevacizumab in combination with chemotherapy. RNA sequencing revealed an association between inflammasome signaling through ZNFX1 and abnormal vasculogenesis. Together, this study identified that ZNFX1 is a tumor suppressor that controls PMR signaling through mitochondria and may serve as a biomarker to facilitate personalized therapy in patients with ovarian cancer. Significance: DNMT and PARP inhibitors induce a nucleic acid sensor, ZNFX1, that serves as a mitochondrial gateway to STING-dependent inflammasome signaling with tumor suppressor properties in ovarian cancer.Keywords
All Related Versions
Funding Information
- National Cancer Institute (P30 CA134274)
- National Institute of Environmental Health Sciences (2R01ES011858)
- National Cancer Institute (1RO1CA259635-01A1)
- National Cancer Institute (1RO1AG078814)
- National Cancer Institute (P50CA254897)
- Van Andel Institute
- Gray Family Foundation
- National Cancer Institute (P50CA228991)
- Adelson Family Foundation
This publication has 46 references indexed in Scilit:
- Multisystem inflammation and susceptibility to viral infections in human ZNFX1 deficiencyJournal of Allergy and Clinical Immunology, 2021
- Interleukin-1β Induces mtDNA Release to Activate Innate Immune Signaling via cGAS-STINGMolecular Cell, 2019
- CEACAM1 structure and function in immunity and its therapeutic implicationsSeminars in Immunology, 2019
- Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung CancerCell, 2017
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous RetrovirusesCell, 2015
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous TranscriptsCell, 2015
- Quantitative PCR-Based Measurement of Nuclear and Mitochondrial DNA Damage and Repair in Mammalian Cells2014
- Emerging role of damage-associated molecular patterns derived from mitochondria in inflammationTrends in Immunology, 2011
- Quantification of mitochondrial DNA (mtDNA) damage and error rates by real-time QPCRMitochondrion, 2009
- ggplot22009